Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2916998 | 0.99 | BACE1 (0.46) | BACE1HRH3KDM2BMEN1KMT2A | |
| SCHEMBL10169283 | 0.87 | HRH3 (0.57) | HRH3MEN1KMT2AKCNH2KDM5A | |
| SCHEMBL6841854 | 0.82 | CCR5 (0.44) | BACE1HRH3KDM2BPKMNPC1 | |
| Hydrochloric Acid SCHEMBL2917972 | 0.82 | CCR5 (0.44) | BACE1HRH3KDM2BMEN1KMT2A | |
| SCHEMBL6847334 | 0.82 | KDM2B (0.68) | BACE1KDM2BMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2915763 | 0.81 | KDM2B (0.67) | BACE1KDM2BMEN1KMT2A | |
| SCHEMBL10169066 | 0.80 | PKM (0.67) | HRH3PKMNPC1ALDH1A1 | |
| SCHEMBL4237007 | 0.71 | HRH3 (0.48) | HRH3KDM2BMEN1KMT2AKCNH2 | |
| SCHEMBL3454773 | 0.71 | MEN1 (0.70) | BACE1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL10211722 | 0.71 | HRH3 (0.53) | HRH3MEN1KMT2AKCNH2KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673829-B2 | TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM, THE PERIPHERAL NERVOUS SYSTEM, THE CARDIOVASCULAR SYSTEM, THE PULMONARY SYSTEM, THE GASTROINTESTINAL SYSTEM AND THE ENDOCRINOLOGICAL SYSTEM. | NOVO NORDISK A/S (DK) | 2004-01-06 | — | — | US | disclosed |
| US-20030130253-A1 | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives | VTVX HOLDINGS II LLC | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130253-A1 | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives | HRH3, HRH1, HRH2 | BACE1 3828/4885HRH3 1/4885KDM2B 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.